Core Insights - Certara, Inc. reported FY 2025 revenue of $418.8 million, reflecting a 9% growth, and an Adjusted EBITDA of $134.5 million, marking a 10% growth [1] - The fourth quarter revenue was $103.6 million, showing a 3% growth year-over-year, while Adjusted EBITDA decreased by 3% to $32.5 million [1][5] - For FY 2026, the company anticipates revenue growth of 0-4%, an Adjusted EBITDA margin of 30-32%, and Adjusted diluted EPS in the range of $0.44-$0.48 [1][19] Financial Performance - Fourth quarter total revenue was $103.6 million, up from $100.4 million in Q4 2024, representing a 3% increase [5][13] - Software revenue for Q4 2025 was $46.4 million, a 10% increase from $42.3 million in Q4 2024, while services revenue was $57.3 million, down 1% from $58.1 million [5][13] - Total bookings for Q4 2025 reached $155.2 million, a 7% increase year-over-year, with software bookings at $56.1 million, down 6%, and services bookings at $99.1 million, up 17% [6][7][13] Operational Insights - The company experienced a net loss of $5.9 million in Q4 2025, compared to a net income of $6.6 million in Q4 2024, primarily due to higher operating expenses [10][12] - Adjusted net income for Q4 2025 was $14.9 million, down from $24.7 million in Q4 2024, with adjusted diluted EPS at $0.09 compared to $0.15 in the previous year [12][13] - Total operating expenses for Q4 2025 were $63.6 million, an increase of $7.5 million from $56.1 million in Q4 2024, driven by higher employee-related costs and professional expenses [9][13] Strategic Outlook - The new CEO, Jon Resnick, emphasized the need for strategic focus and innovation to capture market opportunities and drive sustainable growth in 2026 [3] - The company plans to enhance its product portfolio and commercial execution throughout 2026 to improve revenue growth [3][4] - Certara's technology and customer relationships are seen as strong foundations for long-term success in the AI-enabled biosimulation and drug development market [3]

Core Insights - Certara, Inc. has launched the Non-Animal Navigator™ solution to assist biopharmaceutical companies in adapting to the FDA's Roadmap aimed at reducing animal testing in preclinical safety studies, marking a significant shift in drug development practices [1][3] Group 1: Company Overview - Certara is a global leader in model-informed drug development, providing biosimulation software and services to enhance drug discovery and development processes [5] - The company has over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries [5] Group 2: Industry Context - The FDA's Roadmap is a pivotal moment for the industry, encouraging the adoption of model-informed drug development approaches that are predictive, efficient, and ethical [3] - Monoclonal antibodies and antibody-drug conjugates (ADCs) are in the preclinical phase across various therapeutic areas, with biosimulation models showing predictive capabilities comparable to traditional animal studies [2] Group 3: Product Features - The Non-Animal Navigator offers strategic regulatory advice to design preclinical programs that align with regulatory requirements and utilize new approach methodologies (NAMs) [5] - It includes an integrated preclinical development plan that combines various evidence types, including in vitro, in vivo, and biosimulation data, supported by expert toxicology input [5] - The solution provides access to advanced AI-enabled modeling tools, such as the Simcyp Simulator, to accelerate development timelines [5]